Drug Profile
Interleukin-2 controlled release - Avadel Pharmaceuticals
Alternative Names: IL-2 XLLatest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Flamel Technologies
- Class Adjuvants; Antineoplastics; Immunotherapies; Interleukins; Lymphokines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Renal cancer
Most Recent Events
- 12 Dec 2007 IL-2 XL is available for licensing (http://www.flamel.com)
- 10 Dec 2004 Phase-I/II clinical trials in Renal cancer in France (SC)
- 02 Feb 2004 Preclinical trials in Cancer in France (SC)